Zoetis Inc. $ZTS Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 44.0% in the fourth quarter, Holdings Channel reports. The fund owned 11,983 shares of the company’s stock after selling 9,419 shares during the period. Securian Asset Management Inc.’s holdings in Zoetis were worth $1,508,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB raised its holdings in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after acquiring an additional 550,859 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after acquiring an additional 496,320 shares during the last quarter. Finally, Fundsmith LLP increased its holdings in shares of Zoetis by 25.3% during the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock worth $528,966,000 after buying an additional 730,300 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $76.62 on Tuesday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 52 week low of $76.38 and a 52 week high of $172.23. The stock has a market capitalization of $32.12 billion, a PE ratio of 12.71, a P/E/G ratio of 1.29 and a beta of 0.87. The firm has a 50 day moving average of $116.50 and a two-hundred day moving average of $122.77.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the business earned $1.48 EPS. The business’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts predict that Zoetis Inc. will post 6.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ZTS shares. Citigroup started coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target for the company. BTIG Research restated a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Bank of America raised their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $141.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.